SCHEMBL4123939

SCHEMBL4123939

COc1ccc(CNc2ccc(Cl)cc2C(O)c2cccc(OC)c2C(C)C)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
LPAR1 Q92633 6/20 0.42
APLNR P35414 1/20 0.40
ALDH1A1 P00352 5/20 0.40
KDM4C Q9H3R0 2/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 7/20 0.38
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
CYP1A2 P05177 6/20 0.38
CYP3A4 P08684 6/20 0.38
CYP2D6 P10635 6/20 0.38
CYP2C19 P33261 6/20 0.38
HSD17B10 Q99714 4/20 0.38
CLK4 Q9HAZ1 4/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4119617 0.90 TAS1R3 (0.49) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4122265 0.89 TAS1R3 (0.44) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4121857 0.88 TAS1R3 (0.44) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4116863 0.88 TAS1R3 (0.44) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4122374 0.87 TAS1R3 (0.43) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4113260 0.86 TAS1R3 (0.42) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL8111932 0.86 TAS1R3 (0.47) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4123181 0.86 TAS1R3 (0.42) TAS1R3TAS1R1APLNRALDH1A1KDM4C
SCHEMBL4120083 0.85 TSHR (0.43) TAS1R3TAS1R1LPAR1APLNRALDH1A1
SCHEMBL4123383 0.85 TAS1R3 (0.43) TAS1R3TAS1R1LPAR1APLNRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR TAS1R3 3354/4885TAS1R1 2624/4885LPAR1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.